Abivertinib synergistically strengthens the anti‐leukemia activity of venetoclax in acute myeloid leukemia in a BTK‐dependent manner

B‐cell lymphoma 2 (BCL‐2), a crucial member of the anti‐apoptotic BCL‐2 family, is frequently dysregulated in cancer and plays an important role in acute myeloid leukemia (AML). Venetoclax is a highly selective BCL‐2 inhibitor that has been approved by the FDA for treating elderly AML patients. Howe...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Shujuan Huang, Chenying Li, Xiang Zhang, Jiajia Pan, Fenglin Li, Yunfei Lv, Jingwen Huang, Qing Ling, Wenle Ye, Shihui Mao, Xin Huang, Jie Jin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2020-10-01
Edice:	Molecular Oncology
Témata:	abivertinib AML BTK‐dependent venetoclax
On-line přístup:	https://doi.org/10.1002/1878-0261.12742
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!